COVID Vax Linked to Fivefold Increase in Cancer Biomarker: Cureus Journal of Medical Science

As the world struggles to understand the COVID-19 phenomenon, new studies and reports have emerged exploring the effects of the COVID vaccine on patients with preexisting medical conditions.

A recent case report published in the peer-reviewed medical journal Cureus has shed light on a possible association between the COVID-19 mRNA vaccine and a temporary rise in CA-125 levels.

CA-125 is a transmembrane glycoprotein, a protein attached to the cell’s membrane that plays various roles in cell function, that is an essential biomarker for detecting response to treatment and recurrence of certain cancers.

The case report presented a 79-year-old woman with a history of moderately-differentiated adenocarcinoma of the right adnexa (a type of cancer with moderate abnormal cell growth found in the reproductive organs or nearby tissues on the right side of the body) who had a temporary increase in CA-125 levels after receiving the first dose of the Pfizer-BioNTech COVID mRNA vaccine.

Her CA-125 levels had increased by roughly five times after vaccination, rising from 15.8 U/ml to 78.0 U/ml at her follow-up visit.

This means her cancer biomarker level increased by 4.9 times, or 393.67%, after taking the COVID vaccine.

“She received her first dose of the Pfizer-BioNTech COVID-19 mRNA vaccine on February 10, 2022, and the second dose was received on March 24, 2022,” the study authors write.

“At her follow-up visit on March 7, 2022, routine blood investigations were performed to check her CA-125 levels. Her CA-125 levels had risen to a level of 78.0 U/ml. The level had been within normal limits at her previous visit on October 4, 2021.”

While the exact mechanism that caused the temporary rise in CA-125 levels is unclear, the case report findings strongly suggest that the COVID mRNA jab may be a possible cause.

“Further investigations into the possible effects of COVID-19 mRNA vaccinations and COVID-19 itself on CA-125 levels in patients with ovarian and other gynecological malignancies are warranted,” the authors conclude.

Read the full study below: